Search

Your search keyword '"Janssen, Jeroen J. W. M."' showing total 14 results
Start Over Author "Janssen, Jeroen J. W. M." Publisher american society of hematology
14 results on '"Janssen, Jeroen J. W. M."'

1. Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial

Author

Ngai, Lok Lam, Hanekamp, Diana, Janssen, Fleur, Carbaat-Ham, Jannemieke, Hofland, Maaike A M, Fayed, Mona M H E, Kelder, Angèle, Oudshoorn-van Marsbergen, Laura, Scholten, Willemijn J, Snel, Alexander N, Bachas, Costa, Tettero, Jesse M, Breems, Dimitri A, Fischer, Thomas, Gjertsen, Bjorn T, Griskevicius, Laimonas, Juliusson, Gunnar, van de Loosdrecht, Arjan A, Maertens, Johan A, Manz, Markus G, Pabst, Thomas, Passweg, Jakob R, Porkka, Kimmo, Valk, Peter J M, Gradowska, Patrycja, Löwenberg, Bob, de Leeuw, David C, Janssen, Jeroen J W M, Ossenkoppele, Gert J, Cloos, Jacqueline, Hematology laboratory, VU University medical center, Hematology, AII - Cancer immunology, AII - Inflammatory diseases, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, and CCA - Cancer Treatment and quality of life

Subjects
All institutes and research themes of the Radboud University Medical Center, Immunology, Cell Biology, Hematology, 610 Medicine & health, Biochemistry, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
Abstract

Item does not contain fulltext

Published
2023

2. DNA vs cDNA FLT3-ITD allelic ratio and length measurements in adult acute myeloid leukemia

Author

Cucchi, David G. J., primary, Vonk, Christian M., additional, Rijken, Melissa, additional, Kavelaars, François G., additional, Merle, Pauline A., additional, Verhoef, Elvira, additional, Venniker-Punt, Bianca, additional, Kwidama, Zinia J., additional, Gradowska, Patrycja, additional, Löwenberg, Bob, additional, Janssen, Jeroen J. W. M., additional, Cloos, Jacqueline, additional, and Valk, Peter J. M., additional

Published
2021
Full Text
View/download PDF

3. Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification

Author

van der Werf, Inge, primary, Wojtuszkiewicz, Anna, additional, Meggendorfer, Manja, additional, Hutter, Stephan, additional, Baer, Constance, additional, Heymans, Martijn, additional, Valk, Peter J. M., additional, Kern, Wolfgang, additional, Haferlach, Claudia, additional, Janssen, Jeroen J. W. M., additional, Ossenkoppele, Gert J., additional, Cloos, Jacqueline, additional, and Haferlach, Torsten, additional

Published
2021
Full Text
View/download PDF

5. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Author

Löwenberg, Bob, primary, Pabst, Thomas, additional, Maertens, Johan, additional, Gradowska, Patrycja, additional, Biemond, Bart J., additional, Spertini, Olivier, additional, Vellenga, Edo, additional, Griskevicius, Laimonas, additional, Tick, Lidwine W., additional, Jongen-Lavrencic, Mojca, additional, van Marwijk Kooy, Marinus, additional, Vekemans, Marie-Christiane, additional, van der Velden, Walter J. F. M., additional, Beverloo, Berna, additional, Michaux, Lucienne, additional, Graux, Carlos, additional, Deeren, Dries, additional, de Weerdt, Okke, additional, van Esser, Joost W. J., additional, Bargetzi, Mario, additional, Klein, Saskia K., additional, Gadisseur, Alain, additional, Westerweel, Peter E., additional, Veelken, Hendrik, additional, Gregor, Michael, additional, Silzle, Tobias, additional, van Lammeren-Venema, Daniëlle, additional, Moors, Ine, additional, Breems, Dimitri A., additional, Hoogendoorn, Mels, additional, Legdeur, Marie-Cecile J. C., additional, Fischer, Thomas, additional, Kuball, Juergen, additional, Cornelissen, Jan, additional, Porkka, Kimmo, additional, Juliusson, Gunnar, additional, Meyer, Peter, additional, Höglund, Martin, additional, Gjertsen, Bjorn T., additional, Janssen, Jeroen J. W. M., additional, Huls, Gerwin, additional, Passweg, Jakob, additional, Cloos, Jacqueline, additional, Valk, Peter J. M., additional, van Elssen, Catharina H. M. J., additional, Manz, Markus G., additional, Floisand, Yngvar, additional, and Ossenkoppele, Gert J., additional

Published
2021
Full Text
View/download PDF

6. IGFBP7 activates retinoid acid–induced responses in acute myeloid leukemia stem and progenitor cells

Author

van Gils, Noortje, primary, Verhagen, Han J. M. P., additional, Rutten, Arjo, additional, Menezes, Renee X., additional, Tsui, Mei-Ling, additional, Vermue, Eline, additional, Dekens, Esmée, additional, Brocco, Fabio, additional, Denkers, Fedor, additional, Kessler, Floortje L., additional, Ossenkoppele, Gert J., additional, Janssen, Jeroen J. W. M., additional, and Smit, Linda, additional

Published
2020
Full Text
View/download PDF

7. Insulin-like Growth Factor Binding Protein 7 Activates the Retinoid Acid Differentiation Pathway in Acute Myeloid Leukemia Cells

Author

Van Gils, Noortje, primary, Verhagen, Han J.M.P., additional, Rutten, Arjo, additional, Menezes, Renee X., additional, Tsui, Mei-Ling, additional, Dekens, Esmee, additional, Denkers, Fedor, additional, Vermue, E, additional, Janssen, Jeroen J. W. M., additional, Ossenkoppele, Gert J., additional, and Smit, Linda, additional

Published
2018
Full Text
View/download PDF

9. RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML

Author

Cucchi, David G. J., primary, Denys, Barbara, additional, Kaspers, Gertjan J. L., additional, Janssen, Jeroen J. W. M., additional, Ossenkoppele, Gert J., additional, de Haas, Valérie, additional, Zwaan, C. Michel, additional, van den Heuvel-Eibrink, Marry M., additional, Philippé, Jan, additional, Csikós, Tamás, additional, Kwidama, Zinia, additional, de Moerloose, Barbara, additional, de Bont, Eveline S. J. M., additional, Lissenberg-Witte, Birgit I., additional, Zweegman, Sonja, additional, Verwer, Femke, additional, Vandepoele, Karl, additional, Schuurhuis, Gerrit Jan, additional, Sonneveld, Edwin, additional, and Cloos, Jacqueline, additional

Published
2018
Full Text
View/download PDF

10. Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib

Author

Deenik, Wendy, primary, van der Holt, Bronno, additional, Janssen, Jeroen J. W. M., additional, Chu, Isabel W. T., additional, Valk, Peter J. M., additional, Ossenkoppele, Gert J., additional, van der Heiden, Ilse P., additional, Sonneveld, Pieter, additional, van Schaik, Ron H. N., additional, and Cornelissen, Jan J., additional

Published
2010
Full Text
View/download PDF

12. Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia

Author

Deenik, Wendy, primary, van der Holt, Bronno, additional, Verhoef, Gregor E. G., additional, Smit, Willem M., additional, Kersten, Marie J., additional, Kluin-Nelemans, Hanneke C., additional, Verdonck, Leo F., additional, Ferrant, Augustin, additional, Schattenberg, Anton V. M. B., additional, Janssen, Jeroen J. W. M., additional, Sonneveld, Pieter, additional, van Marwijk Kooy, Marinus, additional, Wittebol, Shulamit, additional, Willemze, Roelof, additional, Wijermans, Pierre W., additional, Westveer, Petra H. M., additional, Beverloo, H. Berna, additional, Valk, Peter, additional, Löwenberg, Bob, additional, Ossenkoppele, Gert J., additional, and Cornelissen, Jan J., additional

Published
2008
Full Text
View/download PDF

13. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Author

Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, Gradowska, Patrycja, Biemond, Bart J, Spertini, Olivier, Vellenga, Edo, Griskevicius, Laimonas, Tick, Lidwine W, Jongen-Lavrencic, Mojca, van Marwijk Kooy, Marinus, Vekemans, Marie-Christiane, van der Velden, Walter J F M, Beverloo, Berna, Michaux, Lucienne, Graux, Carlos, Deeren, Dries, de Weerdt, Okke, van Esser, Joost W J, Bargetzi, Mario, Klein, Saskia K, Gadisseur, Alain, Westerweel, Peter E, Veelken, Hendrik, Gregor, Michael, Silzle, Tobias, van Lammeren-Venema, Daniëlle, Moors, Ine, Breems, Dimitri A, Hoogendoorn, Mels, Legdeur, Marie-Cecile J C, Fischer, Thomas, Kuball, Juergen, Cornelissen, Jan, Porkka, Kimmo, Juliusson, Gunnar, Meyer, Peter, Höglund, Martin, Gjertsen, Bjorn T, Janssen, Jeroen J W M, Huls, Gerwin, Passweg, Jakob, Cloos, Jacqueline, Valk, Peter J M, van Elssen, Catharina H M J, Manz, Markus G, Floisand, Yngvar, and Ossenkoppele, Gert J

Subjects
hemic and lymphatic diseases, 610 Medizin und Gesundheit, 3. Good health
Abstract

Lenalidomide, an antineoplastic and immunomodulatory drug, has therapeutic activity in acute myeloid leukemia (AML), but definitive studies about its therapeutic utility have been lacking. In a phase 3 study, we compared 2 induction regimens in newly diagnosed patients age 18 to 65 years with AML: idarubicine-cytarabine (cycle 1) and daunorubicin and intermediate-dose cytarabine (cycle 2) without or with lenalidomide (15 mg orally on days 1-21). One final consolidation cycle of chemotherapy or autologous stem cell transplantation (auto-SCT) or allogeneic SCT (allo-SCT) was provided according to a prognostic risk and minimal residual disease (MRD)-adapted approach. Event-free survival (EFS; primary end point) and other clinical end points were assessed. A second random assignment in patients in complete response or in complete response with incomplete hematologic recovery after cycle 3 or auto-SCT involved 6 cycles of maintenance with lenalidomide (10 mg on days 1-21) or observation. In all, 392 patients were randomly assigned to the control group, and 388 patients were randomly assigned to lenalidomide induction. At a median follow-up of 41 months, the study revealed no differences in outcome between the treatments (EFS, 44% ± 2% standard error and overall survival, 54% ± 2% at 4 years for both arms) although in an exploratory post hoc analysis, a lenalidomide benefit was suggested in SRSF2-mutant AML. In relation to the previous Dutch-Belgian Hemato-Oncology Cooperative Group and Swiss Group for Clinical Cancer Research (HOVON-SAKK) studies that used a similar 3-cycle regimen but did not pursue an MRD-guided approach, these survival estimates compare markedly more favorably. MRD status after cycle 2 lost prognostic value in intermediate-risk AML in the risk-adjusted treatment context. Maintenance with lenalidomide showed no apparent effect on relapse probability in 88 patients randomly assigned for this part of the study.

14. RNA-based FLT3-YTD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML.

Author

Cucchi, David G. J., Denys, Barbara, Kaspers, Gertjan J. L., Janssen, Jeroen J. W. M., Ossenkoppele, Gert J., de Haas, Valerie, Zwaan, C. Michel, den Heuvel-Eibrink, Marry M. van, Philippe, Jan, Csikós, Tamas, Kwidama, Zinia, de Moerloose, Barbara, de Bont, Eveline S. J. M., Lissenberg-Witte, Birgit I., Zweegman, Sonja, Verwer, Femke, Vandepoele, Karl, Schuurhuis, Gerrit Jan, Sonneveld, Edwin, and Cloos, Jacqueline

Subjects
*RNA, *PROTEIN-tyrosine kinases, *ACUTE myeloid leukemia treatment, *DNA, *CANCER chemotherapy
Abstract

Controversy exists whether internal tandem duplication of FMS-like tyrosine kinase 3 (FLT3-internal tandem duplication [ITD]) allelic ratio (AR) and/or length of the ITD should be taken into account for risk stratification of pediatric acute myeloid leukemia (AML) and whether it should be measured on RNA or DNA. Moreover, the ITD status may be of relevance for selecting patients eligible for FLT3 inhibitors. Here, we included 172 pediatric AML patients, of whom 36 (21%) harbored FLT3-ITD as determined on both RNA and DNA. Although there was a good correlation between both parameters ARspearman = 0.62 (95% confidence interval, 0.22-0.87) and ITDlengthspearman = 0.98 (95% confidence interval, 0.90-1.00), only AR ≥ 0.5 and length ≥48 base pairs (bps) based on RNA measurements were significantly associated with overall survival (AR: Plogrank = .008; ITDlength: Plogrank = .011). In large ITDs (>156 bp on DNA) a remarkable 90-bp difference exists between DNA and RNA, including intron 14, which is spliced out in RNA. Ex vivo exposure (n = 30) to FLT3 inhibitors, in particular to the FLT3-specific inhibitor gilteritinib, showed that colony-forming capacity was significantly more reduced in FLT3-ITD-AR ≥ 0.5 compared with ITD-AR-low and ITD- patient samples (P < .001). RNA-based FLT3-ITD measurements are recommended for risk stratification, and the relevance of AR regarding eligibility for FLT3-targeted therapy warrants further study. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results